Telus Pursues Two Catalysts to Break Its Downtrend: Health Divestiture and AI Expansion
Published on 06/16/2026 at 05:45 | Redaktion boerse-global.de
A near-10% dividend yield typically signals deep trouble, and Telus’ Canadian-listed shares have indeed shed more than 22% since October 2025, flirting with their 52-week low. The stock has lost roughly 8% in 2026 alone, and the RSI sits at 37, underscoring a market that remains deeply skeptical. Yet beneath the surface, management is quietly executing on two strategic fronts that could reframe the narrative — a monetization of the Telus Health unit and an artificial intelligence push through the Telus Digital subsidiary.
The operational picture is actually improving. Net debt to EBITDA has fallen to 3.5 from 3.9 a year ago, with management targeting 3.3 by the end of 2026 and 3.0 by late 2027. Free cash flow rose 19% year-over-year in the first quarter of 2026 to CAD 583 million, helped by a tapering of the capital-intensive fiber and 5G rollout. Telus also holds roughly CAD 3.1 billion in cash and has a CAD 2.75 billion credit facility secured through 2030. Total debt remains formidable at CAD 31 billion against a market cap of around EUR 16 billion, but the deleveraging trajectory is sending encouraging signals to those willing to look past the share price.
Two distinct catalysts are now on the table. The most immediate is the planned sale or partial monetization of Telus Health, a process being advised by TD Securities and Jefferies. CFO Doug French has indicated he hopes to have something “signable or announceable” before new CEO Victor Dodig officially takes over — a tight deadline that, if met, could deliver a revaluation the market has yet to price in. Separately, Telus Digital has signed an exclusive implementation partnership with Cresta, an AI platform focused on voice- and text-based customer service agents as well as real-time human agent support. The unit’s AI-powered services grew 22% in the first quarter, and the Cresta deal targets further gains with global brands. Telus fully re-acquired the Digital spinoff last October, consolidating its digital and AI capabilities under one roof.
Should investors sell immediately? Or is it worth buying Telus?
The stock’s 10% yield is both a lure and a warning. The board has declared a quarterly dividend of CAD 0.4184 per share, payable on July 2, 2026, but management has also made clear the payout is frozen at current levels with no room for growth. Some analysts now believe a dividend cut under Dodig could actually be welcomed by the market, as freed-up capital would accelerate debt reduction. The bear case centers on leverage: with total liabilities of CAD 31 billion, even with progress, the stock remains vulnerable to any earnings miss or delay in the Health process. At CAD 16.62, Telus trades below its 50-day moving average of CAD 17.03, and the technical trend remains pointed lower.
For now, the path to a recovery requires patience. The Health deal is the most powerful near-term re-rating trigger, but it must materialize on a tight timeline. The Cresta partnership, meanwhile, needs to generate measurable revenue uplifts before investors will give Telus Digital credit. Anyone stepping into the stock collects a near-double-digit dividend while waiting on these events, but the uncertainty around timing and the unresolved dividend question means the shares are likely to remain under pressure until either a deal is signed or the new CEO settles the payout debate once and for all.
Ad
Telus Stock: New Analysis - 16 June
Fresh Telus information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
